Compare Gilead Sciences, Inc. (GILD) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Raytheon Technologies Corp — how do they compare? Gilead Sciences, Inc. trades at $134.61 (market cap $163.51B), while Raytheon Technologies Corp trades at $193.1 (market cap $263.80B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RTX | |
|---|---|---|
Market Cap | $163.51B | $263.80B |
Sector | Health | Industrials |
52-Week High | $155.80 | $212.16 |
52-Week Low | $108.22 | $149.17 |
Enterprise Value | $178.05B | $295.92B |
Dividend Yield | 2.49% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
RTX trades at $193.39, down 1.53% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding the $1.51 estimate. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award (PRNewsWire, June 3, 2026), highlight defense sector strength.
Outlook remains positive with analyst consensus price target of $213.00 (69% buy ratings), though elevated P/E of 36.28 poses valuation risk. Key opportunities include defense spending tailwinds and margin expansion, while risks involve debt levels and geopolitical volatility affecting contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
